Article information
Full text is only aviable in PDF
Bibliografía
[1.]
J.L. Pérez Arellano, J.E. Losa García, M.J. García Martín, M.C. Alcázar Montero, J.D. García Palomo, A. Jiménez López.
Patogenia ge neral de la enfermedad pulmonar alveolointersticial difusa.
Rev ClinEsp, 188 (1991), pp. 147-154
[2.]
G. Raghu.
Interstitial lung disease: a diagnostic approach.
Are CT sean and lung biopsy indicated in every patient?. Am J Respir Crit CareMed, 151 (1995), pp. 909-914
[3.]
G.W. Hunninghake, A.R. Kalika.
Approaches to the treatment of pulmonary fibrosis.
Am J Respir Crit Care Med, 151 (1995), pp. 915-918
[4.]
S.H. Lock, N.C. Barnes, A.B. Kay, A. Cyclosporin.
(CsA) as a corti. costeroid sparing agent in corticosteroid dependent asthma.
Thorax, 49 (1994), pp. 1051Q
[5.]
P.H. Godard, P. Chanez, H. Redier, J. Bousquet, F.B. Michel.
New therapeutical approaches in the treatment of asthma.
Ann NY Acad Sci, 725 (1994), pp. 367-377
[6.]
E. Calderón, R.F. Lockey, S.C. Bukantz, R.G. Coffey, D.K. Ledford.
Is there a role for cyclosporine in asthma?.
J Allergy Clin Immunol, 89 (1992), pp. 629-636
[7.]
A.G. Alexander, N.C. Barnes, A.B. Kay.
Trial of cyclosporin in corti-costeroid-dependent chronic severe asthma.
Lancet, 339 (1992), pp. 324-328
[8.]
T. Fukuda, I. Akutsu, S. Motojima, S. Makino.
Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsive-ness by cyclosporin and FK506.
Int Arch Allergy Appl Immunol, 94 (1991), pp. 259-261
[9.]
V. Lagente, C. Carré, F. Kyriacopoulos, E. Boichot, J.M. Mencía-Huerta, P. Braquet.
Inhibitory effect of cyclosporin A on eosinophil infiltration in the guinea-pig lung induced by antigen, platelet-activating factor and leukotriene B4.
Eur Respir J, 7 (1994), pp. 921-926
[10.]
W.J. McCune, D.K. Vallance, J.P. Lynch.
III. Immunosuppressive drug therapy.
Curr Opin Rheumatol, 6 (1994), pp. 262-272
[11.]
E.W.F.W. Aitón, M. Johnson, M. Turner-Warwick.
Advanced crypto-genic fibrosing alveolitis: preliminary report on treatment with cyclosporin A.
Respir Med, 83 (1989), pp. 277-279
[12.]
F. Venuta, E.A. Rendina, P. Ciriano, T. De Giacomo, E. Pompeo, Bachetoni, et al.
Efficacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary fibrosis befare lung transplantation.
J Heart Lung Transplant, 12 (1993), pp. 909-914
[13.]
M. Fukazawa, M. Kawano, S. Hisano, K. Ueda, K. Matsuba.
Efficacy of cyclosporin A for idiopathic pulmonary fibrosis.
Eur J Pediatr, 149 (1990), pp. 441-442
[14.]
J.A. Moolman, P.G. Bardin, D.J. Rossouw, J.R. Joubert.
Cyclosporin as a treatment for interstitial lung disease of unkwnown aetiology.
Thorax, 46 (1991), pp. 592-595
[15.]
W.B. Gruhn, J.A. Díaz-Buxo.
Cyclosporine treatment of steroid resis-tant interstitial pneumonitis associated with dermatomyositis/pol-yomyositis.
J Rheumatol, 14 (1987), pp. 1.045-1.047
[16.]
M. Dahl, A. Chalmers, J. Wade, D. Calverley, B. Munt.
Ten years survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy.
J Rheumatol, 19 (1992), pp. 1.807-1.809
[17.]
J. Alegre, J. Terán, B. Álvarez, J.L. Viejo.
Successful use of cyclosporine for the treatment of aggressive pulonary fibrosis in a patient with rheumatoid arthritis.
Arthritis Rheum, 33 (1990), pp. 1.594-1.596
[18.]
R.A. Roschmann, R.J. Rothenberg.
Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy.
Semin Arthritis Rheum, 16 (1987), pp. 174-185
[19.]
K. Atkinson, D. Bryant, W. Delprado, J. Biggs.
Widespread pulmonary fibrosis as a major clinical manifestation of chronic graft-ver-sus-host disease.
Bone Marrow Transplant, 4 (1989), pp. 129-132
[20.]
J.W. Raschko, M. CottIer-Fox, S.L. Abbondanzo, J.R. Torrisi, T.R. Spitzer, H.J. Deeg.
Pulmonary fibrosis after bone marrow transplantation responsive to treatment with prednisone and cyclosporine.
Bone Marrow Transplant, 4 (1989), pp. 201-205
[21.]
A.S. Rebuck, C.R. Stiller, A.C. Braude, A. Laupacis, R.D. Cohen, K.R. Chapman.
Cyclosporin for pulmonary sarcoidosis.
Lancet, 1 (1984), pp. 174
[22.]
C.A. O’Callaghan, A.U. Wells, A. Lalvani, P.D. Dhillon, D.M. Hansell, D.N. Mitchell.
Effective use of cyclosporin in sarcoidosis: a treatment strategy baded on computed tomography scanning.
Eur Respir J, 7 (1994), pp. 2.255-2.256
[23.]
J.M.J. Hammond, E.D. Bateman.
Successful treatment of life-threatening steroid-resistant pulmonary sarcoidosis with cyclosporin in a patients with systemic lupus erythematosus.
Respir Med, 84 (1990), pp. 77-80
[24.]
A.S. Rebuck, B.R. Sanders, D.K. MacFadden, S.F.P. Man, E.L. York, R.D. Cohén.
Cyclosporin in pulmonary sarcoidosis.
Lancet, 1 (1987), pp. 1.486
[25.]
V.G. Bain, N. Kneteman, N.E. Brown.
Sarcoidosis, liver and cyclosporine.
Ann Intern Med, 119 (1993), pp. 1.148
[26.]
E.L. York, T. Kovithavongs, S.F. Man, A.S. Rebuck, B.J. Sproule.
Cyclosporine and chronic sarcoidosis.
Chest, 98 (1990), pp. 1.026-1.029
[27.]
Y. Martinet, P. Pinkston, C. Saltini, J. Spurzem, J. Muller-Quernheim, R.G. Crystal.
Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis.
Am Rev Respir Dis, 138 (1988), pp. 1.242-1.248
[28.]
L. Bielory, C. Holland, P. Gascon, L. Frohman.
Uveitis, cutaneous and neurosarcoid: treatment with low-dose cyclosporine A.
Transplant Proc, 20 (1988), pp. 144-148
[29.]
A.F. Kavanaugh, S.L. Andrew, B. Cooper, E.C. Lawrence, D.P. Huston.
Cyclosporin therapy of central nervous system sarcoidosis.
Am J Med, 82 (1987), pp. 387
[30.]
F.A. Casavilla, R. Gordon, H.I. Wright, J.S. Gavaler, T.E. Starzl, D.H. Van Thiel.
Clinical course after liver transplantation in patients with sarcoidosis.
Ann Intern Med, 118 (1993), pp. 865-866
[31.]
D. Cunnah, S. Chew, J. Wass.
Cyclosporin for central nervous system sarcoidosis.
Am J Med, 85 (1988), pp. 580-581
[32.]
H. Takizawa, M. Suko, N. Kobayashi, S. Shoji, K. Ohta, M. Nogami, et al.
Experimental hypersensitivity pneumonitis in the mouse: histologic and immunologic features and their modulation with cyclosporin A.
J Allergy Clin Immunol, 81 (1988), pp. 391-400
[33.]
W.C. Kopp, S.E. Dierks, J.E. Butler, B.S. Upadrashta, H.B. Richerson.
Cyclosporine immunomodulation in a rabbit model of chronic hy persensitivity pneumonitis.
Am Rev Respir Dis, 132 (1985), pp. 1.027-1.033
[34.]
M. Denis, Y. Cormier, M. Laviolette.
Murine hypersensitivity pneu monitis: a study of cellular infiltrates and cytokine production and its modulation by cyclosporin A.
Am J Respir Cell Mol Biol, 6 (1992), pp. 68-74
[35.]
J.M. Wang, M. Denis, M. Fournier, M. Laviolette, A. Cyclosporin.
increases the pulmonary eosinophilia induced by inhaled Aspergillus antigen in mice.
Clin Exp Immunol, 93 (1993), pp. 323-330
[36.]
J.E. Salvaggio.
Immune reactions in allergic alveolitis.
Eur Respir J, 4 (1991), pp. 47S-52S
[37.]
J.E. Salvaggio.
Recent advanced in pathogenesis of allergic alveoli tis.
Clin Exp Allergy, 20 (1990), pp. 137-144
[38.]
M.H. Cooper, S.H. Gregory, T.E. Starzl, E.J. Wing.
Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes indu ced by colony-stimulating factors.
Transplantation, 57 (1994), pp. 433-439
[39.]
J.M. Metzger, L.B. Peterson.
Cyclosporin A enhances the pulmonary granuloma response induced by Schistosoma mansimi eggs.
Immunopharmacology, 15 (1988), pp. 103-115
[40.]
G.J. Prud’homme, L.E. Vanier.
Cyclosporine, tolerance and autoimmunity.
Clin Immunol Immunopathol, 66 (1993), pp. 185-192
[41.]
R.V. Bundick, R.I. Graggs, E. Holness.
The effect of cyclosporin A.
FK506 and rapamycin on the murine chronic graft-versus-host response-an in vivo model of Th2-like activity. Clin Exp Immunol, 99 (1995), pp. 467-472
[42.]
A.A. Norris, D.M. Jackson, R.P. Eady.
Protective effects of cyclophosphamide, cyclosporin A and FK506 against antigen-induced lung eosinophilia in guinea-pigs.
Clin Exp Immunol, 89 (1992), pp. 3.437-3.450
[43.]
W. Elwood, J.O. Lotvall, P.J. Bames, K.F. Chung.
Effects of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized BrownNorway rat.
Am Rev Respir Dis, 145 (1992), pp. 1.289-1.294
[44.]
M. Nogami, M. Suko, H. Okudaira, T. Miyamoto, J. Shiga, M. Ito, et al.
Experimental pulmonary eosinophilia in mice by Ascaris suum extract.
Am Rev Respir Dis, 141 (1990), pp. 1.289-1.295
[45.]
C. Richard, J. Calavia, Loyola, J. Baró, M.A. Cuadrado, M.T. Gómez-Ca sases, et al.
Chronic eosinophilic pneumonia in a patients trea ted with allogenic bone marrow transplantation.
Med Clin (Barc), 102 (1994), pp. 462-464
[46.]
G. Feutren, B. Von Graffenried.
Pharmacology of cyclosporin A (Sandimmun®) and clinical experience in inflammatory bowel di-seases.
Schweiz Med Wochenschr, 121 (1991), pp. 748-753
[47.]
G. Feutren.
The optimal use of cyclosporin A in autoimmune diseases.
J Autoimmun, 5 (1992), pp. 183-195
[49.]
H. Valdimarsson.
Immunity during cyclosporine therapy.
J Am Acad Dermatol, 23 (1990), pp. 1.294-1.300
[50.]
B.D. Kahan.
Cyclosporine.
N Engl J Med, 321 (1989), pp. 1725-1.738
[51.]
H. Shennib, R. Padilla-Longoria, R.C.J. Chiu, D.S. Mudler.
Preservation of alveolar macrophage function during immunosuppression: cyclosporin A versus methylprednisolone.
Surg Forum, 33 (1982), pp. 338-341
[52.]
D.B. Drath, B.D. Kahan.
Alterations in rat pulmonary macrophage function by the immunosuppressive agents cyclosporine, azathio-prine, and prednisolone.
Transplantation, 35 (1983), pp. 588-592
[53.]
D.B. Drath, B.D. Kahan.
Phagocytic cell function in response to immunosuppressive therapy.
Arch Surg, 119 (1984), pp. 156-160
[54.]
D.R. Salomón, L.W. Boerth, L.L. Rocher, J.E. Pennington.
Dose-dependent reduction in alveolar macrophage populations during cyclosporine treatment.
Clin Res, 33 (1985), pp. 581A
[55.]
J.P. Lynch III, T.J. Standiford, M.W. Rolfe, S.L. Kunkel, R.M. Strieter.
Neutrophilic alveolitis in idiopathic pulmonary fibrosis.
The role of interleukin-8. Am Rev Respir Dis, 145 (1992), pp. 1.433-1.439
[56.]
J.E. Losa García.
Efecto de la ciclosporina sobre las células del sis tema mononuclear fagocítico. Producción de citocinas inflamato rias [tesis doctoral].
Universidad de Salamanca, (1994),
[57.]
A. Jiménez López, J.E. Losa García, M.J. García Salgado, F. Mateos Rodríguez, C. Disdier, J.L. Pérez Arellano.
Eftect of cyclosporin on inflammatory cytokine production by human alveolar macrophages.
J Hung Soc hit Med, 47 (1994), pp. 89
[58.]
J.A. López Gil, M. García Sáiz.
FK506: ¿un inmunosupresor para los noventa?.
Med Clin (Barc), 101 (1993), pp. 629-636
[59.]
I. Chapman, L. Mazzoni.
Mechanisms of inhibition by cyclosporin A on pulmonary leukocyte accumulation.
Trends Pharmacol Sci, 15 (1994), pp. 99-101
[60.]
R.J. Keenan, A.J. Duncan, S.A. Yousem, M. Zenati, M. Shaper, R.D. Dowling, et al.
Improved immunosuppression with aerosolized cyclosporine in experimental transplantation.
Transplantation, 53 (1992), pp. 20-25
[61.]
R.D. Dowling, M. Zenati, G.J. Burckart, S.A. Yousem, M. Shaper, R.L. Simmons, et al.
Aerosolized cyclosporine as single agent immunotherapy in canine lung allograts.
Surgery, 108 (1990), pp. 198-205
[62.]
T.G. O’Riordan, A. lacono, R.J. Keenan, S.R. Duncan, G.J. Burckart, B.P. Griffith, et al.
Delivery and distribution of aerosolized cyclos porine in lung allograft recipients.
Am J Respir Crit Care Med, 151 (1995), pp. 516-521
[63.]
B.E. Gilbert, S.Z. Wilson, N.M. Garcon, P.R. Wyde, V. Knight.
Characterization and administration of cyclosporine liposomes as a small-particle aerosol.
Transplantation, 56 (1993), pp. 974-977
[64.]
A. Katz, A.G. Coran, K.T. Oldham, K.S. Guice.
Decreased oxidized glutathione with aerosolized cyclosporine delivery.
J Surg Res, 54 (1993), pp. 597-602
Copyright © 1996. Sociedad Española de Neumología y Cirugía Torácica
